Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method

20 Apr 2017

Abstract excerpt

Lymphangioleiomyomatosis (LAM) is included within group 5 of the current PH classification (unclear multifactorial mechanisms). However, data regarding the occurrence of PH in LAM are scarce. The aims of the study were to describe the prevalence and characteristics of PH in a large cohort of LAM patients with different levels of severity, and to evaluate the role of echocardiography and carbon monoxide diffusion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment
Share to Renal cell carcinoma treatment
Share to Tuberous Sclerosis Complex Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28427470
DOI: 10.1186/s13023-017-0626-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening methodPMID 28427470Read ↗

Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management.Semantic proximity Read ↗

Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment.Semantic proximity Read ↗

Emerging clinical picture of lymphangioleiomyomatosis.Semantic proximity Read ↗

Lymphatic manifestations of lymphangioleiomyomatosis.Semantic proximity Read ↗

Recent advances in the management of lymphangioleiomyomatosisSemantic proximity Read ↗

Targeted Approaches toward Understanding and Treating Pulmonary Lymphangioleiomyomatosis (LAM)Semantic proximity Read ↗

New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis.Semantic proximity Read ↗

Pulmonary lymphangioleiomyomatosis.Semantic proximity Read ↗

The Role of Moesin in Diagnosing and Assessing Severity of LymphangioleiomyomatosisSemantic proximity Read ↗

Lymphangioleiomyomatosis: A review.Semantic proximity Read ↗

Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative ‐ Group 3 Pulmonary HypertensionSemantic proximity Read ↗

Clinical and molecular insights into lymphangioleiomyomatosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.